🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being hailed as a "major milestone" in the battle against increasingly resistant strains of the infection, according to researchers.

A Worldwide Challenge

Gonorrhoea infections are increasing around the world, with estimates suggesting more than 82 million instances per year. Especially elevated rates are reported in Africa and nations within the WHO's designated area, which encompasses China and Mongolia to New Zealand. In England, cases have hit a all-time high, while infection numbers across Europe in 2023 were three times higher compared to those in 2014.

“The approval of new treatments for gonorrhoea is an critical and opportune development in the face of growing infection rates, increasing antimicrobial resistance and the highly restricted treatment choices currently available.”

Public health authorities are increasingly worried about the surge in treatment-resistant strains. The World Health Organization has listed it as a "priority pathogen". Recent surveillance revealed that resistance to standard treatments like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Recent Therapies Receive Clearance

Zoliflodacin, alternatively called Nuzolvence, was cleared by the US FDA in December for use against gonorrhoea. This STI can lead to major issues, including the inability to conceive. Researchers anticipate that focused deployment of this new drug will help hinder the development of resistance.

Gepotidacin, developed by the pharmaceutical company GSK, was also approved in close succession. This medication, which is also used to treat UTIs, was shown in trials to be able to combat superbug versions of the gonorrhoea bacteria.

A Unique Approach to Creation

Zoliflodacin stemmed from a unique collaborative effort for drug creation. The non-profit organisation GARDP worked alongside the drug firm its industry partner to see it through.

“This authorization signifies a huge turning point in the therapy of highly resistant gonorrhoea, which until now has been evolving faster than our drug pipeline.”

Clinical Trial Results and Worldwide Availability

As per results detailed in a major medical journal, the new drug eradicated over nine in ten of uncomplicated infections. This establishes an similar efficacy with the typical regimen, which combines an injection and a pill. The research involved over 900 patients from various regions including the United States, Thailand, South Africa, and European nations.

Under the terms of its development partnership, the non-profit has the authority to make available and distribute the drug in numerous low-income and middle-income countries.

Doctors directly involved have voiced hope. The availability of a single-dose, oral treatment of this kind is described as a "game-changer" for public health efforts. This is viewed as crucial to reduce the burden of the infection for patients and to stop the proliferation of extremely resistant gonorrhoea worldwide.